GlassScriptPhysician profile
Teresa E Goebel
NPI 1700085545
$2,245.62
in general payments reported to CMS, 2019-2025
22 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $125 · 2021: $41.76 · 2022: $45.48 · 2023: $609 · 2024: $550 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.33 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $279.61 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Pfizer INC. | $187.54 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.08 | 2020-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $184.84 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $181.36 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $176.86 | 2019-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $160.42 | 2019-2025 | Enhertu |
| Lilly USA, LLC | $135.50 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $130.78 | 2019-2025 | Tecentriq, Polivy |
| Janssen Biotech, INC. | $112.78 | 2020-2025 | Talvey, Tecvayli, Darzalex |
| Celgene Corporation | $108.57 | 2024-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $89.53 | 2019-2023 | Kyprolis, Blincyto |
| Jazz Pharmaceuticals INC. | $72.48 | 2022-2025 | Zepzelca |
| Novartis Pharmaceuticals Corporation | $48.48 | 2019-2020 | |
| Eisai INC. | $46.67 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $37.40 | 2022-2025 | Monjuvi, Zynyz |
| Tersera Therapeutics LLC | $24.99 | 2023 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $20.47 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.50 | 2025 | Onivyde |
| Seagen INC. | $16.99 | 2023 | Adcetris |
| Horizon Therapeutics Plc | $13.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Goebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.